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INTRODUCTION
Epilepsy in patients with brain tumours is common.
The incidence of seizures varies from 20 to 70%
with the highest incidence in low-grade gliomas
(60–70%)1. There is an increasing use of systemic
chemotherapy in patients with brain tumours, and this
raises the concern on the potential of substantial in-
teractions between AEDs and anti-neoplastic agents.
Phenytoin, carbamazepine, phenobarbital, and to a
lesser extent valproate, oxcarbazepine and topiramate,
are metabolised by the hepatic cytochrome P-450
system, especially the CYP 2C9, CYP 2C19, CYP
3A4 and CYP 2B1 iso-enzyme2, 3. To a more or lesser
extent, all these AEDs have inductory or inhibitory
effects on one or more iso-enzymes. Many chemother-
apeutic agents also are metabolised by the hepatic
CYP system4. Glucocorticoids are of special interest
in patients with brain tumours. Dexamethasone is
metabolised by CYP 3A4, and mostly induces it5.
Levetiracetam (LEV), a novel AED, has no known
pharmacological interactions as it has no effect on
mixed function oxidase liver enzymes and has no
protein-binding properties6. Therefore, LEV may be
a particularly useful drug in this group of patients. We
performed a prospective feasibility study to evaluate
the safety and efficacy of LEV in this patient group.
METHODS
Twenty-six patients with primary brain tumour partic-
ipated in the study. Indications to start with LEV were:
persisting seizures, adverse effects of other AEDs
and/or potential drug interactions with anti-neoplastic
agents or glucocorticoids. Patients with potential drug
interactions and no seizures received LEV in a dose of
2000 mg/day; if needed, LEV was raised up to 3000 or
4000 mg/day in the presence of seizures. Efficacy of
seizure control was defined as >50% seizure-reduction
compared with seizure frequency before initiation of
LEV. Adverse effects were recorded using standard-
ised forms. Follow-up took part every 1–3 months. Pa-
tients with low-grade gliomas represented low-grade
astrocytomas and oligodendrogliomas; patients with
high-grade gliomas included anaplastic astrocytoma,
glioblastoma multiforme and anaplastic oligoden-
drogliomas. Patients with newly diagnosed glioblas-
toma multiforme receiving systemic chemotherapy
did so according to a protocol in which temozolomide
was given concomitantly with radiation therapy.
RESULTS
A total of 18 patients with high-grade glioma and 8
with low-grade glioma took part in the study. In the
low-grade glioma group, the most frequent indication
to start LEV was persisting seizures. In the high-grade
glioma group, the potential for drug interactions with
systemic chemotherapy (temozolomide) and/or dex-
amethasone was a frequent indication. The median
follow-up time was 9.3 months.
LEV was added to other AEDs in 25 patients.
In 20 patients with persisting seizures, we found a
seizure-reduction of >50% in 13 (65%) (Table 1).
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Table 1: Results.
Persisting seizures Other indication
High-grade glioma Low-grade glioma High-grade glioma Low-grade glioma
Number 13 7 5 1
Seizure free 2 2 5 1
<50% seizures 6 3 0 0
No effect/increase 5 2 0 0
Adverse events/side-effects 3 2 3 1
LEV continued 13 6 4 1
LEV stopped 0 1 1 0
Other AED stopped 2 5 5 0
These patients were followed for a mean period of
11.8 months (median 12.8, range 3.5–20 months).
In 7 of these 13 patients, the original drug could be
stopped. One patient was started on monotherapy
LEV as initial drug because of potential interactions.
Treatment in this patient was successful during the
follow-up period of 15 months. Of the 20 patients
with persisting seizures 4 became totally seizure free.
Adverse effects were observed in 9 patients (35%),
occasionally more than one per patient. Most fre-
quently reported adverse effects were fatigue, som-
nolence and dizziness and were usually mild. One
patient developed a psychosis 4 weeks after starting
LEV, leading to discontinuation of the drug. One
patient developed a status epilepticus. No significant
changes in blood chemistry were seen.
Our conclusion is that treatment with LEV seems
well feasible in brain tumours. Further investigation
to the place of LEV as monotherapy in brain tumours
seems warranted, including its effects in association
with the use of chemotherapy.
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